Navigating choice in multiple sclerosis management

被引:11
|
作者
Linker, Ralf A. A. [1 ]
Chan, Andrew [2 ]
机构
[1] Univ Regensburg, Dept Neurol, Univ Str 84, D-93053 Regensburg, Germany
[2] Bern Univ Hosp, Ambulantes Neurozent, Inselspital, Freiburgstr 4, CH-3010 Bern, Switzerland
来源
NEUROLOGICAL RESEARCH AND PRACTICE | 2019年 / 1卷 / 01期
关键词
MS therapy; Immunomodulation; Personalized medicine; Treatment monitoring; Disease management; DISEASE-MODIFYING THERAPY; QUALITY-OF-LIFE; INTERFERON-BETA; PHARMACOLOGICAL-TREATMENT; ECTRIMS/EAN GUIDELINE; RECOMMENDATIONS; NATALIZUMAB; ALEMTUZUMAB; PROGNOSIS; PEOPLE;
D O I
10.1186/s42466-019-0005-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundWith the advent of modern immunotherapies for relapsing-remitting multiple sclerosis (RRMS) and the increasing amount of treatment options on the market, MS has evolved as a treatable disease. Yet, at the same time, new challenges for the treating neurologists arise.Main bodyThis review article covers some of these challenges, including when and how to start treatment, treatment monitoring, and finally considerations on what the increasing choice in treatment options brings to disease management and longer-term planning. Among others, these important issues comprise pregnancy, treatment sequencing, switching or even stopping treatment.ConclusionThe ultimate goal for navigating choices in RRMS management is to choose the right drug for the right patient at the right time Throughout the article, there is a strong focus on practical aspects and individual decision making in MS to meet the concept of personalized medicine.
引用
收藏
页数:8
相关论文
共 50 条